ArticleExperimental and therapeutic medicine2015
MicroRNA-124 functions as a tumor suppressor and indicates prognosis in human osteosarcoma.
Article in Experimental and therapeutic medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- MiRNA encoded PTEN's impact on clinical-pathological features and prognosis in osteosarcoma: A systematic review and meta-analysis.PloS one · 2024Pooled it
- Role of MicroRNA-124 as a Prognostic Factor in Multiple Neoplasms: A Meta-Analysis.Disease markers · 2019Pooled it
- Immunotherapy in pediatric bone sarcomas: Current progress and future directions.Human vaccines & immunotherapeutics · 2026Review
- Imaging and molecular mechanisms of pelvic floor electrical stimulation in improving pelvic floor muscle injury in stress urinary incontinence rats.International urology and nephrology · 2026Article
- MicroRNA-124 inhibits cell proliferation, invasion and migration by targeting CAV1 in bladder cancer.Experimental and therapeutic medicine · 2018Article
- MicroRNA-124-3p inhibits cell growth and metastasis in cervical cancer by targeting IGF2BP1.Experimental and therapeutic medicine · 2018Article
- MicroRNAs with prognostic significance in osteosarcoma: a systemic review and meta-analysis.Oncotarget · 2017Article
- miR-124 inhibits proliferation, migration and invasion of malignant melanoma cells via targeting versican.Experimental and therapeutic medicine · 2017Article
- Decreased microRNA-452 expression and its prognostic significance in human osteosarcoma.World journal of surgical oncology · 2016Article
- MicroRNA-200b acts as a tumor suppressor in osteosarcoma via targeting ZEB1.OncoTargets and therapy · 2016Article
- MicroRNA-194 acts as a prognostic marker and inhibits proliferation in hepatocellular carcinoma by targeting MAP4K4.International journal of clinical and experimental pathology · 2015Article
- Identification of a novel molecular probe for recognition of human osteosarcoma cell using the cell-SELEX method.International journal of clinical and experimental medicine · 2015Article
- Ouabain Induces DNA Damage in Human Osteosarcoma U-2 OS Cells and Alters the Expression of DNA Damage and DNA Repair-associated Proteins.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNA-124 (miR-124) has been demonstrated to be downregulated in numerous human malignancies and correlated with tumor progression. However, its expression and clinical significance in osteosarcoma remains unclear. Thus, the aim of the present study was to explore the effects of miR-124 in osteosarcoma tumorigenesis and development. Using reverse transcription-quantitative polymerase chain reaction, miR-124 expression was detected in primary osteosarcoma tissues and osteosarcoma cell lines. The correlation of miR-124 expression with clinicopathological factors and prognosis was statistically analyzed. MTT, flow cytometric, and Transwell invasion and migration assays were used to test the proliferation, apoptosis, invasion and migration of osteosarcoma cells transfected with miR-124 mimic. It was found that the expression levels of miR-124 in osteosarcoma tissues were significantly lower than those in corresponding noncancerous bone tissues (P<0.001). In addition, miR-124 downregulation more frequently occurred in osteosarcoma specimens with advanced clinical stage (P<0.001), positive distant metastasis (P=0.005) and poor response to neoadjuvant chemotherapy (P=0.013). Univariate and multivariate analysis identified low miR-124 expression as an unfavorable prognostic factor for overall survival. Furthermore, transfection of miR-124 mimic into MG63 cells was able to reduce cell proliferation, invasion and migration, and promote cell apoptosis. These findings indicate that miR-124 may act not only as a novel diagnostic and prognostic marker, but also as a potential target for the molecular therapy of osteosarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.